ARVN

Over the past six months, Arvinas experienced several significant stock events. In May 2026, the FDA approved VEPPANU, the first PROTAC therapy, for ER+/HER2- breast cancer, leading to a nearly 10% jump in ARVN shares. Following this approval, VEPPANU was out-licensed to Rigel Pharmaceuticals, generating a $50.0 million milestone payment from Pfizer and $62.5 million in license revenue from Rigel. In August 2026, Q2 financial results highlighted the VEPPANU approval and out-licensing, significantly increasing revenue to $249.7 million. September 2026 saw the initiation of a Phase 1/2 clinical trial for ARV-6723, its first immuno-oncology candidate. In October 2026, Arvinas presented novel data from a Phase 1 clinical trial of ARV-102 in Parkinson's disease. Despite these developments, ARVN stock traded between a high of $14.51 and a low of $6.97 over the past 52 weeks, showing an 11.02% decline over the past year and a 21.64% decrease over the last year, with a monthly fall of -15.91% leading up to October 2026.